Whitehawk Therapeutics (NASDAQ:WHWK) Releases Earnings Results, Beats Expectations By $0.25 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) announced its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.25, Zacks reports. Whitehawk Therapeutics had a negative return on equity of 75.99% and a net margin of 99.42%.

Whitehawk Therapeutics Stock Performance

Whitehawk Therapeutics stock traded down $0.15 during mid-day trading on Thursday, hitting $2.10. 399,210 shares of the company’s stock were exchanged, compared to its average volume of 621,615. The firm has a market capitalization of $98.97 million, a PE ratio of -35.00 and a beta of 0.58. The business has a 50 day moving average price of $2.07. Whitehawk Therapeutics has a 1-year low of $1.39 and a 1-year high of $3.81.

Analyst Ratings Changes

A number of research firms have recently issued reports on WHWK. Zacks Research upgraded Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Wall Street Zen downgraded shares of Whitehawk Therapeutics to a “strong sell” rating in a research note on Saturday, November 1st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Reduce”.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.